BIOCOM for BIOCOM
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocated for passage of FDA User Fee legislation Advocated for legislation that would support greater use of genetic sequencing technologies Advocated for increased utilization and uptake of digital health technologies in health care Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated against the drug pricing provisions of the Inflation Reduction Act Cohosted a Congressional briefing on Anti-microbial resistance Advocated for public health considerations in federal privacy legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE New | — |
Copyright/Patent/Trademark CPT
Advocated for the protection of Intellectual Property rights Advocated for protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the proposals waiving IP protections for covid-19 vaccines, diagnostics, and treatments under the TRIPS agreement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE New | — |
Taxation/Internal Revenue Code TAX
Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Trade (domestic/foreign) TRD
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for passage of the COMPETES Act/USICA Advocated for passage of the CHIPS Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE New | — |
Budget/Appropriations BUD
Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations, including CBER Advocated for increased discretionary funding for the VA appropriations, including the National Pharmacogenomic Program Advocated for increased discretionary funding for all federally funded scientific research institutions
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK New | — |
| RICHARD WHITE | — |
Small Business SMB
Advocated for reauthorization of the SBIR/STTR Program Hosted an FDA/USPTO Roundtable on Strategies for Biotech/Medtech Startups: Successfully Navigating the USPTO and FDA with FDA and USPTO officials.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.